One prospect that has been raised to explain these discrepant results in ApoA1 is that ApoA1, like other neuroinflammatory analytes (sTREM2 and sTNFR2) [48], could increase in the early preclinical phase of AD with an increasing rate of neuropathology burden. This evidence concerns the gene APOA1 and Alzheimer disease.